Based on: Lupus Nephritis — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 52 candidate interventions for lupus Nephritis that are either approved medicines or have at least one registered clinical trial, built on 11 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 1 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- cyclophosphamide — 9 registered trials · investigational · NCT01207297 NCT00774852 NCT00876616
- Fludarabine — 6 registered trials · investigational · NCT06308978 NCT07115745 NCT06708845
- mycophenolate mofetil — 6 registered trials · investigational · NCT00371319 NCT05538208
- Tacrolimus — 4 registered trials · investigational · NCT01207297 NCT00125307 NCT00371319
- Prednisone — 3 registered trials · investigational · NCT02457221 NCT04221477 NCT00774852
- Rituximab — 3 registered trials · investigational · NCT06676631 NCT05508009 NCT05207358
- voclosporin — 2 registered trials · approved medicine · NCT02949973 NCT03597464
- Anifrolumab — 2 registered trials · investigational · NCT05138133 NCT02547922
- CABA-201 — 2 registered trials · investigational · NCT06121297
- Kidney biopsy — 2 registered trials · investigational · NCT06642402 NCT07760480
- LUPKYNIS — 2 registered trials · investigational · NCT05337124 NCT07611214
- Methylprednisolone — 2 registered trials · investigational · NCT04221477 NCT01085097
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in lupus Nephritis and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: C3, CD19, CD38, CTLA4, IFNAR1, IL6, MS4A1, PPP3CA, PPP3CB, TLR7, TNFSF13B.
Which trials are registered?
- Synergetic B-cell Immunomodulation in SLE - 2nd Study. NCT03747159 · Completed · Phase PHASE3 · started 2018-10-01
- Daratumumab to Treat Active Lupus Nephritis NCT04868838 · Active Not Recruiting · Phase PHASE2 · started 2021-04-20
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus NCT06121297 · Recruiting · Phase PHASE1, PHASE2 · started 2024-02-16
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders NCT06434363 · Recruiting · Phase PHASE1, PHASE2 · started 2024-07-31
- To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis NCT07629583 · Recruiting · Phase PHASE1 · started 2026-10-31
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants NCT05039619 · Recruiting · Phase PHASE2 · started 2022-05-12
- Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis NCT07799116 · Recruiting · Phase PHASE1, PHASE2 · started 2026-09-23
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G NCT06419205 · Recruiting · Phase PHASE2 · started 2026-07-30
- Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V NCT05268289 · Recruiting · Phase PHASE2 · started 2022-08-10
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires NCT05567198 · Recruiting · started 2023-03-03
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.